211 related articles for article (PubMed ID: 25680863)
1. Targeting angiogenesis in head and neck cancer.
Vassilakopoulou M; Psyrri A; Argiris A
Oral Oncol; 2015 May; 51(5):409-15. PubMed ID: 25680863
[TBL] [Abstract][Full Text] [Related]
2. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma.
Lingen MW; Polverini PJ; Bouck NP
Cancer Res; 1998 Dec; 58(23):5551-8. PubMed ID: 9850093
[TBL] [Abstract][Full Text] [Related]
5. [Study on the relationship between angiogenesis and cervical lymphatic metastasis in head and neck squamous cell carcinomas].
Zheng H; Lin S
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 May; 17(5):288-90. PubMed ID: 12916359
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
7. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Oh SH; Kim WY; Lee OH; Kang JH; Woo JK; Kim JH; Glisson B; Lee HY
Cancer Sci; 2012 Jul; 103(7):1259-66. PubMed ID: 22494072
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance.
Salven P; Heikkilä P; Anttonen A; Kajanti M; Joensuu H
Mod Pathol; 1997 Nov; 10(11):1128-33. PubMed ID: 9388064
[TBL] [Abstract][Full Text] [Related]
10. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis.
Tae K; El-Naggar AK; Yoo E; Feng L; Lee JJ; Hong WK; Hittelman WN; Shin DM
Clin Cancer Res; 2000 Jul; 6(7):2821-8. PubMed ID: 10914730
[TBL] [Abstract][Full Text] [Related]
11. Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma.
Masuda M; Ruan HY; Ito A; Nakashima T; Toh S; Wakasaki T; Yasumatsu R; Kutratomi Y; Komune S; Weinstein IB
Oral Oncol; 2007 Sep; 43(8):785-90. PubMed ID: 17169602
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
Sauter ER; Nesbit M; Watson JC; Klein-Szanto A; Litwin S; Herlyn M
Clin Cancer Res; 1999 Apr; 5(4):775-82. PubMed ID: 10213212
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid modulates the ability of macrophages to participate in the induction of the angiogenic phenotype in head and neck squamous cell carcinoma.
Liss C; Fekete MJ; Hasina R; Lingen MW
Int J Cancer; 2002 Jul; 100(3):283-9. PubMed ID: 12115542
[TBL] [Abstract][Full Text] [Related]
15. [Coexpression of VEGF and bFGF is associated with increased vascular density in head and neck carcinomas].
Riedel F; Götte K; Schwalb J; Bergler W; Hörmann K
Laryngorhinootologie; 2000 Dec; 79(12):730-5. PubMed ID: 11199455
[TBL] [Abstract][Full Text] [Related]
16. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Sacco AG; Cohen EE
J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas.
Benefield J; Petruzzelli GJ; Fowler S; Taitz A; Kalkanis J; Young MR
Invasion Metastasis; 1996; 16(6):291-301. PubMed ID: 9371228
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy.
Saito K; Khan K; Sosnowski B; Li D; O'Malley BW
Laryngoscope; 2009 Apr; 119(4):665-74. PubMed ID: 19213040
[TBL] [Abstract][Full Text] [Related]
19. CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma.
Marioni G; D'Alessandro E; Giacomelli L; Staffieri A
J Oral Pathol Med; 2010 May; 39(5):361-7. PubMed ID: 20537053
[TBL] [Abstract][Full Text] [Related]
20. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
Huang SM; Li J; Armstrong EA; Harari PM
Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
